Trial Profile
An open label,single dose study evalauating the pharmacokinetics of Apremilast and its metabolite,M12 in subjects with severe renal impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2017
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Renal impairment
- Focus Adverse reactions; Pharmacokinetics
- 09 Jan 2017 New trial record